-
EP3151853
European procedure
Extract from the Register of European Patents
EP About this file: EP3151853
| EP3151853 - GLUTAMIC ACID DECARBOXYLASE (GAD) FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE [Right-click to bookmark this link] | |||
| Former [2017/15] | NOVEL COMBINATIONS FOR ANTIGEN BASED THERAPY | ||
| [2020/10] | Status | No opposition filed within time limit Status updated on 12.03.2021 Database last updated on 08.04.2026 | |
| Former | The patent has been granted Status updated on 03.04.2020 | ||
| Former | Grant of patent is intended Status updated on 27.03.2020 | ||
| Former | Examination is in progress Status updated on 24.03.2020 | ||
| Former | Grant of patent is intended Status updated on 25.02.2020 | ||
| Former | Examination is in progress Status updated on 29.07.2019 | ||
| Former | Request for examination was made Status updated on 10.03.2017 | ||
| Former | The international publication has been made Status updated on 03.01.2017 | Most recent event Tooltip | 06.05.2022 | Change - lapse in a contracting state State(s) deleted from list of lapses: AL | published on 08.06.2022 [2022/23] | Applicant(s) | For all designated states Diamyd Medical AB Kungsgatan 29 111 56 Stockholm / SE | [2017/15] | Inventor(s) | 01 /
ESSEN-MÖLLER, Anders c/o Diamyd Medical AB Kungsgatan 29 S-111 56 Stockholm / SE | 02 /
LUDVIGSSON, Johnny c/o Linköpings Universitet S-581 83 Linköping / SE | [2017/15] | Representative(s) | Zacco Sweden AB P.O. Box 5581 Löjtnantsgatan 21 114 85 Stockholm / SE | [N/P] |
| Former [2017/15] | Zacco Sweden AB P.O. Box 5581 114 85 Stockholm / SE | Application number, filing date | 15802815.9 | 04.06.2015 | [2017/15] | WO2015SE50651 | Priority number, date | SE20140050678 | 04.06.2014 Original published format: SE 1450678 | SE20140051315 | 04.11.2014 Original published format: SE 1451315 | [2017/15] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2015187087 | Date: | 10.12.2015 | Language: | EN | [2015/49] | Type: | A2 Application without search report | No.: | EP3151853 | Date: | 12.04.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 10.12.2015 takes the place of the publication of the European patent application. | [2017/15] | Type: | B1 Patent specification | No.: | EP3151853 | Date: | 06.05.2020 | Language: | EN | [2020/19] | Search report(s) | International search report - published on: | SE | 28.01.2016 | (Supplementary) European search report - dispatched on: | EP | 28.03.2018 | Classification | IPC: | A61K38/51, A61K39/00, A61K31/592, A61K31/593, A61P37/06, A61P3/10 | [2020/10] | CPC: |
A61K39/0008 (EP,IL,US);
A61K31/592 (EP,IL,RU,US);
A61K31/192 (EP,IL,RU,US);
A61K31/197 (EP,IL,US);
A61K31/593 (EP,IL,US);
A61K38/1793 (EP,IL,US);
A61K38/191 (EP,IL,US);
A61K38/28 (EP,IL,RU,US);
A61K38/43 (EP,IL,US);
A61K39/00 (EP,RU,US);
A61K39/44 (RU);
A61K45/06 (EP,IL,US);
A61K9/0019 (EP,IL,US);
A61P3/02 (EP,IL);
A61P3/10 (EP,IL,RU);
A61P37/00 (EP,IL);
A61P37/06 (EP,IL);
A61P43/00 (EP,IL);
C12Y401/01005 (EP,IL,US);
A61K2035/122 (US);
A61K2039/54 (EP,IL,US);
| C-Set: |
A61K31/192, A61K2300/00 (US,EP);
A61K31/197, A61K2300/00 (EP,US);
A61K31/592, A61K2300/00 (EP,US);
A61K31/593, A61K2300/00 (EP,US);
A61K38/191, A61K2300/00 (US,EP);
A61K38/28, A61K2300/00 (EP,US); |
| Former IPC [2020/09] | A61K38/28, A61K39/00, A61P3/10, A61K31/592, A61K31/593, A61P37/00 | ||
| Former IPC [2018/04] | A61K39/00, A61K38/28, A61P3/10, A61K31/592, A61K31/593, A61P37/00 | ||
| Former IPC [2017/15] | A61K39/00, A61P3/10, A61K31/592, A61K31/593, A61K38/28 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/15] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | Title | German: | GLUTAMAT-DECARBOXYLASE (GAD) ZUR VERWENDUNG BEI DER BEHANDLUNG EINER AUTOIMMUNERKRANKUNG | [2020/10] | English: | GLUTAMIC ACID DECARBOXYLASE (GAD) FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE | [2020/10] | French: | LA GLUTAMATE DÉCARBOXYLASE (GAD) POUR LE TRAITEMENT D'UNE MALADIE AUTO-IMMUNE | [2020/10] |
| Former [2017/15] | NEUARTIGE KOMBINATIONEN FÜR ANTIGENBASIERTE THERAPIE | ||
| Former [2017/15] | NOVEL COMBINATIONS FOR ANTIGEN BASED THERAPY | ||
| Former [2017/15] | NOUVELLES COMBINAISONS POUR THÉRAPIE À BASE D'ANTIGÈNE | Entry into regional phase | 02.01.2017 | National basic fee paid | 02.01.2017 | Search fee paid | 02.01.2017 | Designation fee(s) paid | 02.01.2017 | Examination fee paid | Examination procedure | 02.01.2017 | Examination requested [2017/15] | 02.01.2017 | Date on which the examining division has become responsible | 12.10.2018 | Amendment by applicant (claims and/or description) | 01.08.2019 | Despatch of a communication from the examining division (Time limit: M02) | 28.08.2019 | Reply to a communication from the examining division | 26.02.2020 | Communication of intention to grant the patent | 23.03.2020 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 23.03.2020 | Fee for grant paid | 23.03.2020 | Fee for publishing/printing paid | 26.03.2020 | Information about intention to grant a patent | 26.03.2020 | Receipt of the translation of the claim(s) | Divisional application(s) | EP20172919.1 / EP3760224 | Opposition(s) | 09.02.2021 | No opposition filed within time limit [2021/15] | Fees paid | Renewal fee | 16.06.2017 | Renewal fee patent year 03 | 12.06.2018 | Renewal fee patent year 04 | 13.06.2019 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | deleted | [2022/23] |
| Former [2021/04] | AL | 06.05.2020 | Documents cited: | Search | [XYI] WO9712034 (SYNECTICS BIOTECHNOLOGY AB et al.) [X] 1-15 * abstract * * page 1, line 1 - page 15, line 32 * * claim - * * sequence 3 *[Y] 1-15 [I] 1-15 | [XYI] WO9507992 (UNIV CALIFORNIA et al.) [X] 1-15 * abstract * * page 1, line 13 - page 28, line 15 * * example - * * claim - *[Y] 1-15 [I] 1-15 | [XYI] WO2008129426 (DIAMYD THERAPEUTICS AB et al.) [X] 1-15 * abstract * * page 1, paragraph 002 - page 13, paragraph 045 * * page 14, paragraph 056 - page 45, paragraph 0131 * * claim - *[Y] 1-15 [I] 1-15 | [XDYI] US2002107210 (HERRATH MATTHIAS G VON et al.) [XD] 1-15 * abstract * * page 1, paragraph 0001 - page 12, paragraph 0121 * * example - * * claim - *[Y] 1-15 [I] 1-15 | [XI] JEAN-FRANOIS BACH ET AL: "Tolerance to Islet Autoantigens in Type 1 Diabetes", ANNU. REV. IMMUNOL, vol. 19, 1 April 2001 (2001-04-01), England, pages 131 - 161, XP055434511, ISBN: 978-0-7817-2058-8 [X] 1-15 * abstract * * page 138, paragraph 2 - page 143, paragraph 4 * * table 1 *[I] 1-15 | [IY] JIDE TIAN ET AL: "Combining Antigen-Based Therapy with GABA Treatment Synergistically Prolongs Survival of Transplanted -Cells in Diabetic NOD Mice", PLOS ONE, vol. 6, no. 9, 22 September 2011 (2011-09-22), pages e25337, XP055434119, DOI: 10.1371/journal.pone.0025337 [I] 1-15 * abstract * * page 1, column l, paragraph 2 - page 4, column r, paragraph 3 *[Y] 1-15 DOI: http://dx.doi.org/10.1371/journal.pone.0025337 | [IY] MARVIN LIN ET AL: "Reversal of type 1 diabetes by a new MHC II-peptide chimera: "Single-epitope-mediated suppression" to stabilize a polyclonal autoimmune T-cell process", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 40, no. 8, 10 June 2010 (2010-06-10), pages 2277 - 2288, XP055434122, ISSN: 0014-2980, DOI: 10.1002/eji.200940094 [I] 1-15 * abstract * * page 2277, column l, paragraph 1 - page 2287, column l, paragraph 1 *[Y] 1-15 DOI: http://dx.doi.org/10.1002/eji.200940094 | [IY] S. ROBERT ET AL: "Oral Delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 by Lactococcus lactis Reverses Diabetes in Recent-Onset NOD Mice", DIABETES, vol. 63, no. 8, 27 March 2014 (2014-03-27), US, pages 2876 - 2887, XP055351010, ISSN: 0012-1797, DOI: 10.2337/db13-1236 [I] 1-15 * abstract * * page 2876, column l, paragraph 1 - page 2886, column l, paragraph 2 *[Y] 1-15 DOI: http://dx.doi.org/10.2337/db13-1236 | [I] JOHNNY LUDVIGSSON: "The latest pharmacotherapy options for type 1 diabetes", EXPERT OPINION ON PHARMACOTHERAPY, vol. 15, no. 1, 30 November 2013 (2013-11-30), LONDON, UK, pages 37 - 49, XP055434033, ISSN: 1465-6566, DOI: 10.1517/14656566.2014.855197 [I] 1-15 * abstract * * page 37, paragraph 1 - page 45, column r, paragraph 4 * DOI: http://dx.doi.org/10.1517/14656566.2014.855197 | [XYI] TISCH R ET AL: "IMMUNE RESPONSE TO GLUTAMIC ACID DECARBOXYLASE CORRELATES WITH INSULITIS IN NON-OBESE DIABETIC MICE", NATURE, MACMILLAN JOURNALS LTD., ETC, vol. 366, 4 November 1993 (1993-11-04), pages 72 - 75, XP002909567, ISSN: 0028-0836, DOI: 10.1038/366072A0 [X] 1-15 * page 72 - page 75 *[Y] 1-15 [I] 1-15 DOI: http://dx.doi.org/10.1038/366072a0 | [XYI] IVAN C GERLING ET AL: "The Thymus as a Site for Evaluating the Potency of Candidate [beta] Cell Autoantigens in NOD Mice", JOURNAL OF AUTOIMMUNITY, vol. 7, no. 6, 1 December 1994 (1994-12-01), pages 851 - 858, XP055434921, DOI: 10.1006/jaut.1994.1068 [X] 1-15 * abstract * * page 851 - page 858 * [Y] 1-15 [I] 1-15 DOI: http://dx.doi.org/10.1006/jaut.1994.1068 | International search | [A] WO2005102374 (DIAMYD MEDICAL AB et al.) | [X] PRESS RELEASE: "Ny klinisk studie med Diamyds diabetesvaccin", WEDNESDAY, 30 January 2013 (2013-01-30), XP055362420, Retrieved from the Internet | [X] LUDVIGSSON J.: "Novel therapies in the managemant of type I diabetes mellitus", PANMINERVA MEDICA, vol. 54, no. 4, 2012, pages 257 - 270, XP008185339 | [X] DATABASE EudraCT [o] 25 July 2012 (2012-07-25), "Pilot trial to preserve residual insulin secretion in children and adolescents with recent onset Type 1 diabetes by using GAD- antigen (Diamyd) therapy in combination with vitamin D and ibuprofen", XP055363340, Database accession no. 2012-003251-11; | [X] DATABASE EudraCT [o] 24 April 2015 (2015-04-24), "Open label trial to evaluate the tolerability of a combination therapy consisting of GAD-alun (Diamyd), etanercept and vitamin D in children and adolescents newly diagnosed with type 1 diabetes", XP055363353, Database accession no. 2014-001323-76; | by applicant | US2002107210 | MOCELLIN, CYTOKINE GROWTH FACTOR REV., 2004 | RUSSEL ET AL., ISLETS, 2014 | CALCINARO ET AL., DIABETOLOGIA, 2005 | VAN DONGEN ET AL., INT J CANCER, vol. 127, no. 4, 15 August 2010 (2010-08-15), pages 899 - 909 | LOUVET ET AL., PROC NATL ACAD SCI USA, 2008 | AGOSTINOET ET AL., J ONCOL PHARM PRACT., 2010 | ADORINI, ANN N Y ACAD SCI., 2003 | HEINE ET AL., EUR J IMMUNOL., 2008 | NIIRO ET AL., BIOCHEM BIOPHYS RES COMMUN., 1998 | OBERMAJER ET AL., BLOOD, 2011 | LIEB, MED HYPOTHESES, 2007 | KIM ET AL., IMMUNE NETW., 2010 | GRIBBEN ET AL., IMMUNOLOGY, 1994 | POSADAS ET AL., CLINICAL IMMUNOLOGY, 2009 | PATAKAS ET AL., ACR/ARHP, 2013 | SHERRYHAGOPIANLUDVIGSSON ET AL., LANCET, 2011 | ORBAN ET AL., DIABETES CARE, 2013 | VERHAGEN ET AL., PLOS, 2014 | DENES ET AL., DIABETES TECHNOL THER., 2010 | ROBERT ET AL., DIABETES, 2014 | SKYLER ET AL., DIABETES, 2011 | STAEVA ET AL., DIABETES, vol. 62, January 2013 (2013-01-01) | SKYLER, DIABETES TECHNOLOGY & THERAPEUTICS, vol. 16, no. 1, 2014 | RIGBY ET AL., CURRENT OPINION ENDOCRINOL DIABETES OBES, vol. 21, 2014, pages 271 - 278 | HOMANN ET AL., J. IMMUNOL., vol. 163, 1999, pages 1833 - 1838 | AULTON, M.E.: "Pharmaceutics: The Science of Dosage Forms", 2002, MARCEL DEKKER, INC. | "The Theory and Practice of Industrial Pharmacy", 1986, LEA & FEBIGER | "Handbook of Pharmaceutical Excipients", July 2009, AMERICAN PHARMACEUTICAL ASSOCIATION | BAEKKESKOV ET AL., NATURE, vol. 347, 1990, pages 151 | PALMER ET AL., SCIENCE, vol. 222, 1983, pages 1337 | DANIEL ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1995, pages 956 - 960 | WONG ET AL., NAT. MED., vol. 5, 1999, pages 1026 - 1031 | CHEN ET AL., J. IMMUNOL., vol. 167, 2001, pages 4926 - 4935 | RUDY ET AL., MOL. MED., vol. 1, 1995, pages 625 - 633 | RAZ ET AL., LANCET, vol. 358, 2001, pages 1749 - 53 | RABIN ET AL., J. IMMUNOL., vol. 152, 1994, pages 3183 | SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR | "Current Protocols in Immunology", vol. 4, JOHN WILEY & SONS, INC. |